ArticleGastroenterology report2017
Novel treatment options for portal hypertension.
Article in Gastroenterology report, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Pharmacological Modulation of Liver and Spleen Stiffness in a Cirrhotic Rat Model.Hepatic medicine : evidence and research · 2025Article
- Recent Approaches in Portal Hypertension Involving Risk Stratification and Medical Management.Gastroenterology & hepatology · 2023Article
- Article
- Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives.Biomedicines · 2022Review
- Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.Hepatology (Baltimore, Md.) · 2022Article
- Downregulation of CaFrontiers in pharmacology · 2022Article
- Review
- Review
- Review
- Drug for heart is applicable to liver: Is it possible?Journal of the Chinese Medical Association : JCMA · 2020Article
- Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.International journal of molecular sciences · 2020Review
- CARVEDILOL AS PRIMARY PROPHYLAXIS FOR GASTRIC VARICEAL BLEEDING IN PORTAL HYPERTENSION MODEL IN RATS.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2020Article
- Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.World journal of gastroenterology · 2019Article
- The future of therapy for alcoholic hepatitis - Beyond corticosteroids.Journal of hepatology · 2019Article
- Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats.Journal of visualized experiments : JoVE · 2018Article
- The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats.Scientific reports · 2018Article
- Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.Digestive diseases and sciences · 2018Review
- Managing portal hypertension in patients with liver cirrhosis.F1000Research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portal hypertension is most frequently associated with cirrhosis and is a major driver for associated complications, such as variceal bleeding, ascites or hepatic encephalopathy. As such, clinically significant portal hypertension forms the prelude to decompensation and impacts significantly on the prognosis of patients with liver cirrhosis. At present, non-selective β-blockers, vasopressin analogues and somatostatin analogues are the mainstay of treatment but these strategies are far from satisfactory and only target splanchnic hyperemia. In contrast, safe and reliable strategies to reduce the increased intrahepatic resistance in cirrhotic patients still represent a pending issue. In recent years, several preclinical and clinical trials have focused on this latter component and other therapeutic avenues. In this review, we highlight novel data in this context and address potentially interesting therapeutic options for the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.